ProCE Banner Activity

Patient Resource: Understanding Treatment Options for Advanced ALK-Positive NSCLC 

PDF

Download this short PDF developed in partnership with lung cancer experts to increase your understanding of treatment options for advanced ALK-positive NSCLC, including questions to ask your doctor and key side effects to monitor for. 

Released: May 07, 2025

Expiration: November 06, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by an educational grant from Pfizer Inc.

Pfizer Inc.

Disclosure

Primary Author

Todd M. Bauer, MD: consultant/advisor/speaker: Bayer, FMI, Pfizer, Tempus.

Christine Bestvina, MD: consultant/advisor/speaker: AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, EMD Serono, Genentech, Gilead, Guardant, Johnson & Johnson, Mirati, Novocure, Pfizer, Sanofi, Tempus, Turning Point Therapeutics; researcher (paid to institution): AstraZeneca, Bristol Myers Squibb; other financial or material support: AstraZeneca, Bristol Myers Squibb, Guardant, Johnson & Johnson.

Jessica J. Lin, MD: consultant/advisor/speaker: AnHeart Therapeutics, AstraZeneca, Bayer, Blueprint Medicines, Bristol Myers Squibb, C4 Therapeutics, Claim Therapeutics, Daiichi Sankyo, Elevation Oncology, Ellipses, Genentech, Gilead, Janssen, Lilly, Merus, Mirtati Therapeutics, Novartis, Nuvation Bio, Nuvalent, Pfizer, Regeneron, Roche, Takeda, Turing Point Therapeutics, Yuhan; researcher (paid to institution): Bayer, Elevation Oncology, Hengrui Therapeutics, Linnaeus Therapeutics, Neon Therapeutics, Novartis, Nuvalent, Roche, Relay Therapeutics, Turning Point Therapeutics; other (travel support): Bristol Myers Squibb, Merus, Pfizer, Takeda.

Beth Sandy, MSN, CRNP, FAPO: consultant/advisor/speaker: Amgen, AstraZeneca, Jazz, Lilly, Merck, Pfizer, Takeda.